tbuckley/cabot-search huggingface dataset:
TGFB1 Functional Polymorphisms in Sibling HSCT. "Tto be or Not Tto be"
Authors: Mariano Berro, Virginia Palau, Maria Marta Rivas, Maria Cecilia Foncuberta, Adriana Vitriu, Guillermina Remaggi, Gregorio Jaimovich, Alejandro Requejo, Juliana Martinez Rolon, Irene Larripa, Karin Padros, Maria Beatriz Rodriguez, Carolina Barbara Belli, Gustavo Daniel Kusminsky, Leonardo J Feldman
Journal: Blood (2015)
Intensive Care Unit Bed Availability and Use of Mechanical Ventilation in Nursing Home Residents With Advanced Dementia
Authors: Gary S. Winzelberg, Laura C. Hanson
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Screening for ATM sequence alterations in African-American women diagnosed with breast cancer
Authors: A. E. Hirsch, D. P. Atencio, B. S. Rosenstein
Journal: Journal of Clinical Oncology (2006)

10037 Background: Women who are heterozygous for mutations in the ATM gene, ATM carriers, are reported to have an increased risk of breast cancer compared with noncarriers of the mutation. There are few data on breast cancer susceptibility mutations in African-American women, particularly the non-BRCA mutations. We set out to determine whether there is evidence that ATM represents a breast cancer susceptibility gene in African-American women. Methods: One hundred thirty-two African-American women were screened for ATM sequence alterations. Thirty-seven (28%) were women with a histological diagnosis of breast cancer (cases) and 95 (72%) were age-matched women who were seen for a screening mammogram and had no evidence of cancer (controls). Genetic variants were identified using Denaturing High-Performance Liquid Chromatography (DHPLC). Results: Eighteen of 37 (49%) cases and 54/95 (57%) possessed at least one ATM variant (p =0.256). Missense variants were seen on 16/37 (43%) cases and 66/95 (69%) controls. In addition, 5/37 cases and 24/95 controls possessed multiple ATM sequence variants (p=0.107). The most common polymorphisms were: 378 T -&gt;A, seen on 7/37 (19%) cases and 26/95 (27%) controls (p=0.219); 2685 A-&gt; G, seen on 5/37 (11%) cases and 7/95 (6%) controls (p=0.217); and 1254 A-&gt; G, seen on 2/37 (3%) cases and 9/95 (9%) controls (p=0.357). There were no significant differences in any of the single nucleotide polymorphisms (SNPs) detected between the cases and controls. Conclusions: We found no significant differences in the overall frequency of ATM variants between African-American women with breast cancer and an age-matched cohort of African-American women without breast cancer. ATM, therefore, does not appear to represent a breast cancer susceptibility gene in the African-American population. Many of the ATM variants that we found in high frequency were consistent with prior reports of common variants in patients of African ancestry. Comparing the difference in the frequency of ATM variants in the African-American population screened in this study with prior reports on non-African-American subjects will enable us to characterize the differential distribution of genetic alterations in various patient populations and lead to more optimally tailored cancer therapy. No significant financial relationships to disclose.
A new molecular link between defective autophagy and erythroid abnormalities in chorea-acanthocytosis
Authors: Francesca Lupo, Elena Tibaldi, Alessandro Matte, Alok K. Sharma, Anna Maria Brunati, Seth L. Alper, Carlo Zancanaro, Donatella Benati, Angela Siciliano, Mariarita Bertoldi, Francesca Zonta, Alexander Storch, Ruth H. Walker, Adrian Danek, Benedikt Bader, Andreas Hermann, Lucia De Franceschi
Journal: Blood (2016)
TCT-579 Stent Strut Coverage and Stent Apposition After Implantation of a Novel Drug-Filled Coronary Stent: Optical Coherence Tomography Results from RevElution Trial
Authors: Stephen G. Worthley, Alexandre Abizaid, Ajay J. Kirtane, Daniel Simon, Stephan Windecker, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2015)
Maintenance Treatment with Azacytidine for Patients with High Risk Myelodysplastic Syndromes or Acute Myeloid Leukaemia in Complete Remission after Intensive Chemotherapy.
Authors: Michael Grövdal, Rasheed Khan, Anni Aggerholm, Petar Antunovic, Jan Astermark, Per Bernell, Lena-Maria Engström, Lars Kjeldsen, Olle Linder, Lars Nilsson, Anna Olsson, Jonas Wallvik, Jon Magnus Tangen, Gunnar Öberg, Sten Eirik Jacobsen, Peter Hokland, Anna Porwit, Eva Hellström-Lindberg
Journal: Blood (2007)
Analysis of Factors Involved in Malignant Progression of Anaplastic Large Cell Lymphoma Kinase (ALK) -Negative Anaplastic Large Cell Lymphoma.
Authors: Tsuyoshi Nakamaki, Takashi Maeda, Hidetoshi Nakashima, Masamichi Hattori, Takako Usui, Shigeru Tomoyasu, Yoshio Honma
Journal: Blood (2004)
Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma
Authors: Caroline G. Watts, Anne E. Cust, Scott W. Menzies, Graham J. Mann, Rachael L. Morton
Journal: Journal of Clinical Oncology (2016)

Purpose Clinical guidelines recommend that people at high risk of melanoma receive regular surveillance to improve survival through early detection. A specialized High Risk Clinic in Sydney, Australia was found to be effective for this purpose; however, wider implementation of this clinical service requires evidence of cost-effectiveness and data addressing potential overtreatment of suspicious skin lesions. Patients and Methods A decision-analytic model was built to compare the costs and benefits of specialized surveillance compared with standard care over a 10-year period, from a health system perspective. A high-risk standard care cohort was obtained using linked population data, comprising the Sax Institute’s 45 and Up cohort study, linked to Medicare Benefits Schedule claims data, the cancer registry, and hospital admissions data. Benefits were measured in quality-adjusted life-years gained. Sensitivity analyses were undertaken for all model parameters. Results Specialized surveillance through the High Risk Clinic was both less expensive and more effective than standard care. The mean saving was A$6,828 (95% CI, $5,564 to $8,092) per patient, and the mean quality-adjusted life-year gain was 0.31 (95% CI, 0.27 to 0.35). The main drivers of the differences were detection of melanoma at an earlier stage resulting in less extensive treatment and a lower annual mean excision rate for suspicious lesions in specialized surveillance (0.81; 95% CI, 0.72 to 0.91) compared with standard care (2.55; 95% CI, 2.34 to 2.76). The results were robust when tested in sensitivity analyses. Conclusion Specialized surveillance was a cost-effective strategy for the management of individuals at high risk of melanoma. There were also fewer invasive procedures in specialized surveillance compared with standard care in the community.
Efficacy of a Russian-backbone live attenuated influenza vaccine among children in Senegal: a randomised, double-blind, placebo-controlled trial
Authors: John C Victor, Kristen D C Lewis, Aldiouma Diallo, Mbayame N Niang, Bou Diarra, Ndongo Dia, Justin R Ortiz, Marc-Alain Widdowson, Jodi Feser, Rebecca Hoagland, Shannon L Emery, Kathryn E Lafond, Kathleen M Neuzil
Journal: The Lancet Global Health (2016)

BackgroundLive attenuated influenza vaccines have been shown to significantly reduce influenza in diverse populations of children, but no efficacy studies have been done in resource-poor tropical settings. In Senegal, we assessed the efficacy and safety of a live attenuated influenza vaccine based on Russian-derived master donor viruses and licensed as a single dose.MethodsIn this double-blind, placebo-controlled, parallel group, single-centre trial done near Niakhar, Senegal, generally healthy children aged 2–5 years were randomly allocated (2:1) to receive a single intranasal dose of masked trivalent live attenuated influenza vaccine or placebo. The allocation sequence was computer-generated by PATH with block sizes of three. The manufacturer provided vaccine and placebo in coded vials to preserve blinding. Participants were monitored through the predictable influenza season in Senegal for adverse events and signs and symptoms of influenza using weekly home visits and surveillance in clinics. The primary outcome was symptomatic laboratory-confirmed influenza caused by any strain and occurring from 15 days post-vaccination to the end of the study. The primary analysis was per protocol. This study is registered with ClinicalTrials.gov, number NCT01854632.FindingsBetween May 23, and July 1, 2013, 1761 children were randomly assigned, 1174 to receive live attenuated influenza vaccine and 587 to receive placebo. The per-protocol set included 1173 vaccinees and 584 placebo recipients followed up to Dec 20, 2013. Symptomatic influenza was laboratory-confirmed in 210 (18%) of 1173 recipients of live attenuated influenza vaccine and 105 (18%) of placebo recipients, giving a vaccine efficacy of 0·0% (95% CI −26·4 to 20·9). Adverse events were balanced between the study groups. Two girls who had received live attenuated influenza vaccine died, one due to anasarca 12 days postvaccination and one due to malnutrition 70 days postvaccination.InterpretationLive attenuated influenza vaccine was well tolerated in young children in Senegal, but did not provide protection against influenza. Further study in such populations, which might experience extended periods of influenza circulation, is warranted.FundingUS Centers for Disease Control and Prevention and Bill & Melinda Gates Foundation.
Poor Prognosis Associated with FAB Subtypes M4 and M5 in Japanese Pediatric Acute Myeloid Leukemia Patients with FLT3-ITD
Authors: Yusuke Hara, Norio Shiba, Kentaro Ohki, Myoung-ja Park, Akira Shimada, Daisuke Tomizawa, Akiko Moriya Saito, Junichiro Fujimoto, Tomohiko Taki, Akitoshi Kinoshita, Takashi Taga, Hirokazu Arakawa, Akio Tawa, Keizo Horibe, Souichi Adachi, Yasuhide Hayashi
Journal: Blood (2014)
Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (aGVHD); A Multicenter Phase I/II Study
Authors: Yukiyasu Ozawa, Tatsunori Goto, Kazuteru Ohashi, Makoto Murata, Tetsuya Eto, Naoki Kobayashi, Shuichi Taniguchi, Masahiro Imamura, Kiyoshi Ando, Shunichi Kato, Takehiko Mori, Takanori Teshima, Masaki Mori, Kazuo Muroi, Koichi Miyamura, Keiya Ozawa
Journal: Blood (2011)
A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma
Authors: Zain A. Husain, Tiange Chen, Christopher D. Corso, Zoheng Wang, Henry Park, Benjamin Judson, Wendell Yarbrough, Hari Deshpande, Saral Mehra, Phoebe Kuo, Roy H. Decker, Barbara A. Burtness
Journal: JAMA Oncology (2016)

The current American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) staging system, developed for human papillomavirus (HPV)-unrelated disease, discriminates poorly when applied to HPV-related oropharyngeal squamous cell cancer (OPSCC), leading to calls for a new staging system.To compare the prognostic ability of the AJCC/UICC seventh edition staging system; a recently proposed system, the International Collaboration on Oropharyngeal Cancer Network for Staging (ICON-S); and a novel objectively derived system for HPV-related OPSCC using a national database of patients primarily treated with either radiation or surgery.In this observational study, patients with HPV-related nonmetastatic OPSCC were identified in the National Cancer Database between 2010 and 2012. Recursive partitioning analysis (RPA) was used to derive the proposed-RPA staging system. The data were analyzed from March to May 2016.Overall survival was calculated using the Kaplan-Meier method. The performance of the 3 systems was compared using published criteria, and internal validation using bootstrap methods was performed. Survival differences between stage groups were evaluated using the log-rank test.A total of 5626 patients (86.0% male; median [range] age, 58 [21-90] years) were identified. The median (range) follow-up was 28.5 (0.1-58.8) months. A novel staging system (proposed-RPA) consisting of stage IA, T1-2N0-2a; stage IB, T1-2N2b-3; stage II, T3N0-3; stage III, T4a-bN0-3 resulted in 3-year overall survival rates of 91%, 87%, 81%, and 70%, respectively. This system, as well as the ICON-S, significantly prognosticated for survival when either primary surgery or primary radiation subgroups were examined (log-rank P < .001 for all). The AJCC/UICC system, ICON-S, and proposed-RPA all significantly predicted survival outcomes when analyzed globally (log-rank P < .001 for all). The AJCC/UICC system could not differentiate between survival when stages I and IVA were compared, however (log-rank P = .17). On comparative performance evaluation for survival prediction, the proposed-RPA provided superior prognostication compared with the other systems.We validated the ICON-S staging as prognostic, overall, and in primary radiation therapy and surgery subgroups, but ultimately found that a staging system consisting of stage IA, T1-2N0-2a; stage IB, T1-2N2b-3; stage II, T3N0-3; and stage III, T4a-bN0-3 (with stage IV representing M1 disease) outperformed the others. The proposed-RPA is an alternative staging system that should be evaluated for potential adoption as part of the next AJCC/UICC staging system.
P1.38: Relationship Between TILs and Neutrophil-Lymphocyte Ratio as a Prognostic Factor in Advanced NSCLC
Authors: Eduardo Richardet, Patricia A. Hernandez, Martin Richardet, Luciana Acosta, Matias Molina, Evelin Pets, Luciano Dicalbo, Rocio Villavicencio, Martin Paradelo
Journal: Journal of Thoracic Oncology (2016)
Treatment of adolescent young adults with acute lymphoblastic leukemia: 10-year outcome data from a single institution.
Authors: Phat Le, Jennie York Law, Bao Duy Dao, Chul Ahn, Kirthi Kumar, Larry Don Anderson, Robert Collins, Hsiao Ching Li, Prapti Arvind Patel, Navid Sadeghi, Madhuri Vusirikala, Pier P. Scaglioni, Harris V. K. Naina
Journal: Journal of Clinical Oncology (2015)

e18047 Background: Compared to children with acute lymphoblastic leukemia (ALL), adolescent young adults (AYA, age 15-39) with ALL have lower rates of survival. Routine incorporation of asparaginase (ASP) may account for improved outcomes of pediatric patients. Several studies demonstrate improved clinical outcomes with use of pediatric inspired protocols to treat AYA. Methods: We performaed a retrospective analysis of consecutive patients diagnosed with ALL from 2004-2014 at UT Southwestern Medical Center and its associated county hospital, Parkland Hospital. Demographic, disease, treatment, and outcome data were obtained from the hospital electronic medical record. Results: A total of 107 ALL patients were identified, 44 were AYA. Mean age was 26 years, 77% were Hispanic, and 61% were treated at Parkland Hospital. The median OS for the entire AYA cohort was 30 months at a median follow up of 19 months. Initial regimens included Hyper-CVAD (57%), CALGB 10403 (11%) and “other” regimens (32%). “Other” regimens included various pediatric protocols or the treatment was unknown. There was no statistically significant difference in survival among the initial regimens used. 80% of the patients achieved a complete remission with CALGB 10403 or HyperCVAD as an initial regimen. 30 patients received ASP compared to 14 patients who did not during the course of their treatment. The median OS for these two groups was 48 months vs. 18 months (p = 0.7), respectively. Reasons for not receiving ASP were treatment prior to 2011 (n = 6) when use of pediatric protocols for AYA was not widespread and presence of Ph-positive ALL (n = 5). There was insufficien data in the medical record to explain the lack of ASP administration in the remaining patients. Conclusions: We did not observe a difference in outcomes in regards to the initial regimen (HyperCVAD vs. CALGB 10403), nevertheless our data demonstrates a trend towards improved outcomes for AYA treated with ASP containing regimens, which is in accordance with the current literature. Larger prospective studies will be needed to determine equivalency or superiority of either of these regimens for treatment of ALL in AYA.
Radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC): Results from a randomized, placebo-controlled, phase II study
Authors: S. Nilsson, L. Franzén, C. Tyrrell, R. Blom, J. Tennvall, B. Lennernäs, D. C. Johannessen, M. Sokal, C. Parker, Ø. S. Bruland
Journal: Journal of Clinical Oncology (2007)

5071 Background: The alpha emitter radium-223 is a bone-seeking radionuclide studied as a novel treatment for patients with HRPC and bone metastases. Ra-223 showed minimal toxicity in a phase 1 study (Nilsson S, et al., Clin Cancer Res 2005;11 (12): 4451–59). Here we present outcome data from a randomised phase II study. Methods: Patients with HRPC and bone pain requiring external beam radiotherapy were randomized to treatment with 4 injections of either Ra-223 (50 kBq/kg b.w.) or saline (placebo) every 4 weeks. The primary endpoints were change in bone-alkaline phosphatase (ALP) levels from baseline to 4 weeks after last injection (previously reported (Bruland ØS, et al. Clin Cancer Res 2006;12:6250s-57s), and time to occurrence of Skeletal Related Events (SREs). Secondary endpoints included toxicity, PSA progression and overall survival. Results: 33 patients were randomised to Ra-223 and 31 to placebo. The two groups were well balanced with respect to standard prognostic factors. Mild, transient haematological toxicity was seen after Ra-223. Long term toxicity was not observed. SAEs were observed in 8 patients in the Ra-223 group versus 14 in the placebo group. Based on intention to treat analysis, the median time to PSA progression was 26 versus 8 weeks (p=0.047) for Ra-223 versus placebo, respectively. The median time to first SRE was 28 versus 26 weeks (p= 0.164). The median overall survival was 65.3 weeks versus 46.4 weeks (p = 0.066). The hazard ratio for overall survival, adjusted for baseline PSA, albumin, LDH and performance status was 2.11 (95 % CI: 1.08 - 4.13, p=0.029). At 18 months, 15 (45%) versus 8 (26%) patients patients were still alive. Conclusions: Alpharadin was extremely well tolerated, with minimal myelotoxicity, and with encouraging evidence of efficacy. Larger clinical trials are warranted to study the impact of Alpharadin on the prevention of SREs and on overall survival in HRPC. The bone targeting properties of Alpharadin, may also be applicable to the treatment of skeletal metastasis from other primary cancers. [Table: see text]
Oncologyeducation.com: The development and use of a web-based educational resource for medical oncology professionals
Authors: R. L. Lee, S. Verma, J. Chung, L. Wood, C. Butts, S. Vijayaratnam, S. R. Berry
Journal: Journal of Clinical Oncology (2008)

17538 Background: Improving physicians’ access to information and continuing medical education (CME) opportunities will likely contribute to optimal patient care. The internet offers an innovative resource for medical oncology professionals (MOs) to share important medical advances. Hence, we surveyed Canadian MOs to determine their use of the internet, assessed their needs for an educational website and developed www.oncologyeducation.com based on that needs assessment. Here we describe the results of the survey and the use of the website since its launch in May 2007. Methods: A structured survey was distributed by mail and email to Canadian MOs to assess their use of the internet and features they considered important in an educational website. Website statistics for Oncologyeducation.com from June 1, 2007 to Nov 30, 2007 was gathered using Google Analytics. Results: 207/408 MOs responded to our survey for an overall response rate of 51%. 73% of respondents accessed the internet up to 10 hours weekly and the most common reasons for internet use were email, literature updates, answering clinical questions and accessing practice guidelines. Oncologyeducation.com currently has 239 registered members, which represents about 60% of Canadian MOs. The website received 4,350 visits from 2,059 unique visitors. 53% of visitors returned to Oncologyeducation.com at least once per month and 18% accessed the website more than 15 times per month. Although Canadian MOs represented the majority of visits, 30% came from 55 countries outside Canada. Visitors from developing countries viewed more pages and spent more time on site than visitors from developed countries. The most-viewed pages each month consistently included the medical oncologists’ database search page, oncology conferences page, and informational update pages. Conclusions: Oncologyeducation.com is used by Canadian and international visitors with the most popular pages reflecting content requested in the initial needs assessment. The numbers of international visitors suggest an opportunity to provide CME and informational updates for MOs worldwide especially in developing countries. No significant financial relationships to disclose.
Rituximab Combined to ACVBP (R-ACVBP) Supported by Pegfilgrastim as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Results of LNH 03–39B. A GELA Study.
Authors: Karim Belhadj, Jean-Philippe Jais, Pierre Feugier, Christian Gisselbrecht, Christian Recher, Olivier Casasnovas, Bertrand Coiffier, Catherine Sebban, Alain Delmer, Franck Morschhauser, Daniele Canioni, Herve Tilly, Corinne Haioun
Journal: Blood (2007)
Eating oats reduces three markers of cardiovascular risk, finds study
Authors: Jacqui Wise
Journal: BMJ (2016)

Eating oats is associated with a modest reduction in low density lipoprotein (LDL) cholesterol as well as reducing non-high density lipoprotein (non-HDL) cholesterol and apolipoprotein B, a systematic review and meta-analysis has shown.1

Previous studies have focused on the effect of eating oats on concentrations of LDL cholesterol, but there is growing evidence that non-HDL cholesterol (measured by subtracting total cholesterol from HDL …
Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results
Authors: Gareth J Morgan, Faith E. Davies, Walter M. Gregory, Sue E. Bell, Alex J. Szubert, Nuria Navarro-Coy, Mark T. Drayson, Roger G. Owen, Gordon Cook, Fiona M. Ross, Graham H. Jackson, J. Anthony Child
Journal: Blood (2010)